First global report on atopic dermatitis launched to provide insight into the worldwide prevalence and burden of the disease.

The report comprehensively summarizes the disease burden, geographical gaps in prevalence data, the impact on patients’ and their families’ lives as well as currently available treatments. It also takes stock of inequalities in access to therapeutics and provides horizon scanning on novel treatment approaches.

Atopic dermatitis is a highly prevalent, non-communicable chronic skin disease – also known as ‘atopic eczema’ or ‘eczema’. Dry, flaky and itchy skin is a hallmark feature. Atopic dermatitis affects up to 20% of children and 10% of adults, with a particularly high prevalence in young children.

However, most epidemiological surveys have been conducted in higher income countries, and there is lack of data on how many people have atopic dermatitis in many lower resource settings, its severity, and how it is treated. This knowledge is essential to better understand the global and local burden of atopic dermatitis and to plan public health interventions to improve patients’ lives.

Following the publication of the first global report, GADA aims to fill gaps in epidemiological data and provide recommendations for governments, policymakers, health professionals and patient organisations based on best evidence through:

About the Global Atopic Dermatitis Atlas

The GADA project is led by Professor Carsten Flohr and is an initiative of the ILDS in collaboration with the International Society of Atopic Dermatitis (ISAD), the International Eczema Council (IEC), the European Taskforce for Atopic Dermatitis (ETFAD) and the International Alliance of Dermatology Patient Organizations (GlobalSkin).

For further information or questions, please contact info@atopicdermatitisatlas.org or visit the website.